Press Release: Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Dow JonesFeb 18 08:04 ET

Evolus: Strategic Developments and FDA Approvals Drive Buy Rating With Promising Growth Projections

TipRanksFeb 17 03:15 ET · Ratings

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Zacks Feb 14 07:55 ET

An Excellent Week for Evolus, Inc.'s (NASDAQ:EOLS) Institutional Owners Who Own 70% as One-year Returns Inch Higher

Simply Wall StFeb 14 07:47 ET

Investors Appear Satisfied With Evolus, Inc.'s (NASDAQ:EOLS) Prospects As Shares Rocket 59%

Simply Wall StFeb 14 07:44 ET

Breaking Down Evolus: 4 Analysts Share Their Views

BenzingaFeb 14 07:00 ET